Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Rapid Determination of SARS-CoV-2 Antibodies Using a Bedside, Point-of-Care, Serological Test
33 Pages Posted: 30 Apr 2020More...
BACKGROUND: Despite over 70 rapid diagnostic tests (RDT) for SARS-CoV-2 currently in some stage of development or use, many have failed, few have been validated on more than a few samples, and none provide medical practitioners with an easy-to-use, self-contained, bedside test with high accuracy.
METHODS: Two hundred fifty-six sera from 101 patients hospitalized with SARS-CoV-2 infection (positive RT-PCR) were tested for IgM and IgG using the NG-Test IgM-IgG COVID all-in-one assay (NG Biotech). The seroconversion dynamic was assessed by symptom onset and the day of RT-PCR diagnosis. Fifty control sera were also tested to assess specificity.
FINDINGS: The NG-Test IgM-IgG COVID All-in-one identified 16.8% of RT-PCR-positive patients as SARS-CoV-2 the day PCR testing was performed, but specific IgM and/or IgGs were detected in over 50% and 98% of patients at 8 and 15 days after the onset of symptoms, respectively. Sensitivity, specificity, Positive Predictive Value and Negative Predictive Value were 97·0%, 100%, 100% and 96·2%, respectively 15 days after the onset of symptoms. No difference in seroconversion delay was observed regardless of whether patients received ventilation.
INTERPRETATION: This valuable serological assay could serve as a complementary source of diagnostic information to RT-PCR and chest imaging. It may also be useful to monitor medical and non-medical workers during the ongoing pandemic or during subsequent waves, and to monitor the immunological status of the general population after social distancing measures have eased. The assay can be used as a bedside tool or used in a general practitioner’s office.
FUNDING STATEMENT: This research was supported by Assistance Publique – Hôpitaux de Paris (APHP), Médecins Sans Frontières (MSF), and by a Grant from the French Defence Innovation Agency (AID).
DECLARATION OF INTERESTS: The authors declare no conflict of interest.
ETHICS APPROVAL STATEMENT: The use of samples was reviewed and approved by the local Ethics Committee under CPP N° CO-15-000.
Keywords: COVID-19; Serology; Diagnosis; Rapid Test; Diagnostics; Bedside
Suggested Citation: Suggested Citation